emactuzumab

Cisplatin + anti-CSF-1R versus cisplatin + anti-CSF-1R + anti-IFNAR1: P = 0.0064 (two-tailed log-rank test). b, log2 ratio of intratumoural expression levels of 28 type I ISGs in emactuzumab (anti-CSF-1R)-treated patients (n = 31 patients) normalized against the pre-treatment expression levels. c, Box plots of the expression level of the 11 statistically significant upregulated type I ISGs in tumours of emactuzumab-treated patients (data from b, indicated by asterisks). Expression levels in the pre-treatment (baseline) tumour biopsies are compared to on-treatment (emactuzumab) biopsies. The top-most line is the maximum, the top of the box is the third quartile, the centre line is the median, the bottom of the box is the first quartile and the bottom-most line is the minimum. RPKM, reads per kilobase of exon per million mapped reads. The P values were determined by a two-tailed Student's t-test.